Semaglutide studies: 1,194 papers with results
Page 11 of 24
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
Kurozumi A · Diabetology international · 2023
Non-randomized trial · 20 results
- Semaglutide improves markers of cardiovascular risk in people with HIV.
Lake JE · AIDS (London, England) · 2026
Non-randomized trial · 8 results
- Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.
Yang F · International journal of surgery (London, England) · 2025
Non-randomized trial · 11 results
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Granhall C · Clinical pharmacokinetics · 2018
Non-randomized trial · 6 results
- Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Marbury TC · Clinical pharmacokinetics · 2017
Non-randomized trial · 7 results
- Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
Ditzenberger GL · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
Non-randomized trial · 5 results
- Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.
Hauge C · Expert opinion on drug metabolism & toxicology · 2021
Non-randomized trial · 4 results
- Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
Jordy AB · Clinical pharmacokinetics · 2021
Non-randomized trial · 9 results
- Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.
Lake JE · HIV medicine · 2026
Non-randomized trial · 1 result
- The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.
Bouhajib M · Journal of basic and clinical physiology and pharmacology · 2025
Non-randomized trial · 2 results
- Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
Iacobellis G · Journal of the Endocrine Society · 2020
Non-randomized trial · 8 results
- Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Bækdal TA · Clinical pharmacokinetics · 2019
Non-randomized trial · 6 results
- Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Hausner H · Clinical pharmacokinetics · 2017
Non-randomized trial · 7 results
- GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
Rodbard HW · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2019
Non-randomized trial · 8 results
- Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Cronenberger C · Journal of clinical pharmacology · 2026
Non-randomized trial · 1 result
- Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.
Kishimori T · Scientific reports · 2025
Observational study · 8 results
- Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
Tan X · Diabetes, obesity & metabolism · 2026
Observational study · 2 results
- Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults.
Katsura M · Diabetes, obesity & metabolism · 2026
Observational study · 14 results
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Krüger N · JAMA · 2025
Observational study · 5 results
- Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
Ostrominski JW · Diabetes care · 2026
Observational study · 8 results
- Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.
Kuo CC · Hepatology communications · 2025
Observational study · 10 results
- Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.
Kishimori T · Open heart · 2025
Observational study · 4 results
- Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.
Saeed A · Annals of internal medicine · 2025
Observational study · 8 results
- Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
Wilson L · Diabetes, obesity & metabolism · 2026
Observational study · 8 results
- Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.
Kishimori T · European heart journal. Quality of care & clinical outcomes · 2025
Observational study · 6 results
- Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
Kishimori T · Diabetes, obesity & metabolism · 2026
Observational study · 2 results
- Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.
Ruseva A · Advances in therapy · 2025
Observational study · 9 results
- Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
Ulrich FS · The Lancet regional health. Europe · 2026
Observational study · 14 results
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
Lähteenvuo M · JAMA psychiatry · 2025
Observational study · 12 results
- Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.
Zhang J · Journal of orthopaedic surgery and research · 2025
Observational study · 7 results
- Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.
le Roux CW · Journal of endocrinological investigation · 2026
Observational study · 8 results
- Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.
Monzo L · ESC heart failure · 2026
Observational study · 8 results
- Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.
Pratley RE · BMJ open · 2020
Observational study · 11 results
- Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.
Yu Z · Frontiers in endocrinology · 2026
Observational study · 7 results
- Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
Brown RE · Diabetes, obesity & metabolism · 2020
Observational study · 7 results
- Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.
Bonora BM · Diabetes/metabolism research and reviews · 2025
Observational study · 9 results
- Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.
Menzen M · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
Observational study · 4 results
- Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
Napoli R · Diabetes, obesity & metabolism · 2023
Observational study · 8 results
- Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
Mohammedi K · Diabetes, obesity & metabolism · 2023
Observational study · 7 results
- Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
García de Lucas MD · Frontiers in endocrinology · 2023
Observational study · 9 results
- Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.
Pérez-Velasco MA · Medicina clinica · 2025
Observational study · 4 results
- Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.
Baalmann A · Journal of managed care & specialty pharmacy · 2026
Observational study · 8 results
- Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.
Caruso P · Diabetes, obesity & metabolism · 2025
Observational study · 2 results
- PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
Saravanan P · Advances in therapy · 2024
Observational study · 9 results
- Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.
Fadini GP · Diabetes, obesity & metabolism · 2025
Observational study · 5 results
- Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.
Ghusn W · International journal of obesity (2005) · 2024
Observational study · 12 results
- Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.
Alabduljabbar K · Endocrine · 2024
Observational study · 8 results
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
Rajamand Ekberg N · Primary care diabetes · 2021
Observational study · 5 results
- Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.
Giaccari A · Diabetes research and clinical practice · 2026
Observational study · 6 results
- REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.
Cárdenas-Salas JJ · Journal of diabetes and its complications · 2024
Observational study · 7 results